+

WO2011067348A3 - Mek inhibitor salts and solvates thereof - Google Patents

Mek inhibitor salts and solvates thereof Download PDF

Info

Publication number
WO2011067348A3
WO2011067348A3 PCT/EP2010/068763 EP2010068763W WO2011067348A3 WO 2011067348 A3 WO2011067348 A3 WO 2011067348A3 EP 2010068763 W EP2010068763 W EP 2010068763W WO 2011067348 A3 WO2011067348 A3 WO 2011067348A3
Authority
WO
WIPO (PCT)
Prior art keywords
solvates
mek inhibitor
indolizine
phenylamino
tetrahydro
Prior art date
Application number
PCT/EP2010/068763
Other languages
French (fr)
Other versions
WO2011067348A2 (en
Inventor
Liladhar Murlidhar Waykole
Piotr H. Karpinski
Original Assignee
Novartis Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Novartis Ag filed Critical Novartis Ag
Publication of WO2011067348A2 publication Critical patent/WO2011067348A2/en
Publication of WO2011067348A3 publication Critical patent/WO2011067348A3/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

The present invention relates to sodium salt forms of 7-(4-Bromo-2-fluoro- phenylamino)-6-methyl-5-oxo-1,3,5-tetrahydro-indolizine-8-carboxylic acid (2- hydroxyethoxy)-amide and 7-(4-Bromo-2-fluoro-phenylamino)-5-oxo- 1,2,3,5-tetrahydro- indolizine-8-carboxylic acid cyclopropylmethoxy-amide and their corresponding solvates and polymorphs, which are useful in the treatment of a disease, disorder or syndrome associated with MEK inhibition, such as cancer, in mammals.
PCT/EP2010/068763 2009-12-03 2010-12-02 Mek inhibitor salts and solvates thereof WO2011067348A2 (en)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US26641009P 2009-12-03 2009-12-03
US61/266,410 2009-12-03
US26684209P 2009-12-04 2009-12-04
US61/266,842 2009-12-04

Publications (2)

Publication Number Publication Date
WO2011067348A2 WO2011067348A2 (en) 2011-06-09
WO2011067348A3 true WO2011067348A3 (en) 2011-08-04

Family

ID=44009944

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/EP2010/068763 WO2011067348A2 (en) 2009-12-03 2010-12-02 Mek inhibitor salts and solvates thereof

Country Status (1)

Country Link
WO (1) WO2011067348A2 (en)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2013109142A1 (en) 2012-01-16 2013-07-25 Stichting Het Nederlands Kanker Instituut Combined pdk and mapk/erk pathway inhibition in neoplasia
WO2015041533A1 (en) 2013-09-20 2015-03-26 Stichting Het Nederlands Kanker Instituut Rock in combination with mapk-pathway
WO2015041534A1 (en) 2013-09-20 2015-03-26 Stichting Het Nederlands Kanker Instituut P90rsk in combination with raf/erk/mek
US20170027940A1 (en) 2014-04-10 2017-02-02 Stichting Het Nederlands Kanker Instituut Method for treating cancer
WO2015178770A1 (en) 2014-05-19 2015-11-26 Stichting Het Nederlands Kanker Instituut Compositions for cancer treatment

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20090275606A1 (en) * 2008-04-21 2009-11-05 Novartis Ag Heterocyclic Compounds as MEK Inhibitors

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7666901B2 (en) 2004-10-13 2010-02-23 Wyeth Analogs of 17-hydroxywortmannin as PI3K inhibitors
CA2599320A1 (en) 2005-02-25 2006-08-31 Kudos Pharmaceuticals Limited Hydrazinomethyl, hydr zonomethyl and 5-membered heterocylic compounds which act as mtor inhibitors and their use as anti cancer agents
EP1871377A1 (en) 2005-02-25 2008-01-02 Kudos Pharmaceuticals Ltd 2,4-diamino-pyridopyrimidine derivatives and their use as mtor inhibitors
CA2628920C (en) 2005-11-22 2015-12-29 Kudos Pharmaceuticals Limited Pyrido-,pyrazo- and pyrimido-pyrimidine derivatives as mtor inhibitors
BRPI0706395A2 (en) 2006-01-11 2011-03-22 Astrazeneca Ab compound, use thereof, methods for producing an antiproliferative effect in a warm-blooded animal and for treating disease, pharmaceutical composition, and process for preparing a compound
ES2648388T3 (en) 2006-08-23 2018-01-02 Kudos Pharmaceuticals Limited Derivatives of 2-methylmorpholin pyrido-, pyrazo- and pyrimido-pyrimidine as mTOR inhibitors
EP2227469B9 (en) 2007-11-12 2014-09-10 Takeda Pharmaceutical Company Limited Mapk/erk kinase inhibitors

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20090275606A1 (en) * 2008-04-21 2009-11-05 Novartis Ag Heterocyclic Compounds as MEK Inhibitors

Also Published As

Publication number Publication date
WO2011067348A2 (en) 2011-06-09

Similar Documents

Publication Publication Date Title
HK1225733B (en) Dual mechanism inhibitors for the treatment of disease
BRPI1013426A2 (en) organisms for the production of 1,3-butanediol
MX2009013990A (en) Methods of treating serotonin-mediated diseases and disorders.
MX297669B (en) Production of terephthalic acid di-esters.
SMT201700529T1 (en) METHODS FOR INCREASED PROTEIN PRODUCTION
PL2324831T3 (en) Pirfenidone therapy with the exclusion of fluvoxamine
FI20095836L (en) Probiotic preparation for the prevention or treatment of gastrointestinal disorders in dogs
BRPI1008021A2 (en) Method for the manufacture of 2,6-dioxabicyclo- (3.3.0) -octane-4,8-dione
IL208350A0 (en) Aminodihydrothiazine derivatives as bace inhibitors for the treatment of alzheimer's disease
AP2012006227A0 (en) Derivatives of purine or deazapurine useful for the treatment of inter, alia viral, infections.
WO2012025944A3 (en) Sitagliptin, salts and polymorphs thereof
PH12012500278A1 (en) Substituted xanthine derivatives
IT1394503B1 (en) SALTS OF 6'-SIALILLATTOSE AND PROCESS FOR THEIR SYNTHESIS AND FOR THE SYNTHESIS OF OTHER ALPHA-SIALYLOLIGOSACCHARIDES.
HRP20130476T1 (en) Imidazopyridine derivatives which inhibit the secretion of gastric acid
IN2012DN01642A (en)
MX2012005225A (en) N-7 substituted purine and pyrazolopyrimidine compounds, compositions and methods of use.
WO2011067348A3 (en) Mek inhibitor salts and solvates thereof
WO2010046926A3 (en) Novel stilbene analogs
EP2243486A4 (en) PROMOTER OF ADRENOMEDULLIN PRODUCTION
WO2011067356A3 (en) Polymorphs of a mek inhibitor
FR2947265B1 (en) PROCESS FOR THE PREPARATION OF ALKYLALCANOLAMINES
FR2941435B3 (en) FLOATING STRUCTURE, BOAT OR SIMULAR
WO2011027359A3 (en) Process for the preparation of 4 -hydroxy atomoxetine and intermediates in the manufacture thereof
IT1398835B1 (en) MACHINING CENTER FOR THE REALIZATION OF LIGNEAN WINDOW PARTS.
WO2010109185A3 (en) Process for the preparation of doxazosin and salts thereof

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 10784318

Country of ref document: EP

Kind code of ref document: A1

NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 10784318

Country of ref document: EP

Kind code of ref document: A2

点击 这是indexloc提供的php浏览器服务，不要输入任何密码和下载